Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Gilead Sciences
Gilead Sciences
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Rousselot
Rousselot is the global leader* of collagen-based solutions for the food, health and nutrition, biomedical and pharmaceutical sectors. Working in partnership with our global...
Causes and solutions for dark spots in tablet manufacturing
Natoli Engineering examines the causes and solutions for dark spots that can halt production
Donaldson's Isolere Bio launches IsoTag reagent for optimal AAV purification
The IsoTag AAV reagent can purify adeno associated viruses for research purposes, achieving up to an 85% in yield
Novo Nordisk's haemophilia A/B drug Alhemo gets positive opinion from the EMA
The subcutaneous, self-administering prophylactic can allow a patient to produce thrombin, a clotting agent, even in the presence of inhibitors
groninger showcases filling and closing solutions for OTC pharma at Pack Expo
Discover the flexcare 101 and flexfill machines designed for enhanced efficiency and flexibility in pharmaceutical production
Upcoming event
Lab Innovations
30-31 October 2024 | Exhibition | Birmingham, UK
See all
Related Content
Ingredients
Therapeutic: seladelpar for primary biliary cholangitis
The chronic and progressive autoimmune liver disease, primary biliary cholangitis, affects the bile ducts running through the liver and slowly degrades them
Distribution
PANTHERx Rare and Gilead Sciences partner to distribute Livdelzi
The therapeutic is approved for the use in patients with primary biliary cholangitis, and can be used in tandem with UDCA or as a monotherapy
Research & Development
Hookipa and Gilead amend HIV immunotherapy agreement
Under the original agreement, Gilead would assume rights for further development following a joint research phase
Finance
Gilead acquires Immunomedics for $21bn
The transaction is anticipated to close during Q4 2020
Ingredients
Cipla signs COVID-19 licensing agreement with Gilead Sciences
Indian Cipla will be permitted to manufacture US-based Gilead’s API and finished product of Remdesivir and market it in 127 countries including India and South Africa under its own brand name
Research & Development
Hookipa Gilead collaboration reaches major milestones
The license agreement to focus on HBV and HIV has now delivered 24 research-grade vectors
Media
GlobalData publishes analysis of top 25 global pharma companies
The data and analytics company has tracked the market cap performance of the top 25 pharma companies for the quarter ending 31 March, 2018 compared to 2017 revealing a number of interesting insights
Subscribe now